Tags

Type your tag names separated by a space and hit enter

The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
Parkinsonism Relat Disord. 2013 Nov; 19(11):1053-6.PR

Abstract

BACKGROUND

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease (PD). The most common genetic mutation associated with PD identified to date is the G2019S mutation of the LRRK2 gene, which is highly prevalent in the Ashkenazi Jewish population. The effect of STN-DBS surgery in patients carrying this mutation has not been systematically studied. We therefore performed a case-control study to evaluate the impact of the G2019S mutation status on the outcomes of bilateral STN-DBS.

METHODS

The study sample included 39 Jewish PD patients with bilateral STN-DBS. Thirteen patients (5 females) were G2019S mutation heterozygous. The control group consisted of 26 PD patients with bilateral STN-DBS, negative for the mutation, matched (2:1) for gender, age at PD onset, and disease duration at surgery. Clinical data including the Unified PD Rating Scale scores (UPDRS), levodopa equivalent daily dose (LEDD), and clinical global impression of change (CGIC) concerning both motor and neuropsychiatric outcome- were available at 3 time points (preoperative baseline, 6-12 months and 3 years postoperatively).

RESULTS

Implementing a linear mixed model, a significant improvement (p < 0.05) was found for the whole group concerning reduction in motor UPRDS (off state) and LEDD pre- vs. postoperatively, as expected. No difference in clinical outcome was found between carriers and matched non-carriers at baseline or at postoperative follow-up (up to 3 years).

CONCLUSIONS

In our study, STN-DBS outcomes were not influenced by the LRRK2 G2019S mutation, and thus knowledge of carrier status may not be relevant to the considerations of patient selection for surgery.

Authors+Show Affiliations

Department of Neurology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Parkinson's disease and Movement Disorders Clinic, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23932063

Citation

Greenbaum, Lior, et al. "The LRRK2 G2019S Mutation Status Does Not Affect the Outcome of Subthalamic Stimulation in Patients With Parkinson's Disease." Parkinsonism & Related Disorders, vol. 19, no. 11, 2013, pp. 1053-6.
Greenbaum L, Israeli-Korn SD, Cohen OS, et al. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease. Parkinsonism Relat Disord. 2013;19(11):1053-6.
Greenbaum, L., Israeli-Korn, S. D., Cohen, O. S., Elincx-Benizri, S., Yahalom, G., Kozlova, E., Strauss, H., Molshatzki, N., Inzelberg, R., Spiegelmann, R., Israel, Z., & Hassin-Baer, S. (2013). The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease. Parkinsonism & Related Disorders, 19(11), 1053-6. https://doi.org/10.1016/j.parkreldis.2013.07.005
Greenbaum L, et al. The LRRK2 G2019S Mutation Status Does Not Affect the Outcome of Subthalamic Stimulation in Patients With Parkinson's Disease. Parkinsonism Relat Disord. 2013;19(11):1053-6. PubMed PMID: 23932063.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease. AU - Greenbaum,Lior, AU - Israeli-Korn,Simon D, AU - Cohen,Oren S, AU - Elincx-Benizri,Sandra, AU - Yahalom,Gilad, AU - Kozlova,Evgenia, AU - Strauss,Hanna, AU - Molshatzki,Noa, AU - Inzelberg,Rivka, AU - Spiegelmann,Roberto, AU - Israel,Zvi, AU - Hassin-Baer,Sharon, Y1 - 2013/08/06/ PY - 2013/02/27/received PY - 2013/06/01/revised PY - 2013/07/05/accepted PY - 2013/8/13/entrez PY - 2013/8/13/pubmed PY - 2014/6/28/medline KW - LRRK2 KW - Parkinsons disease KW - STN-DBS SP - 1053 EP - 6 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 19 IS - 11 N2 - BACKGROUND: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease (PD). The most common genetic mutation associated with PD identified to date is the G2019S mutation of the LRRK2 gene, which is highly prevalent in the Ashkenazi Jewish population. The effect of STN-DBS surgery in patients carrying this mutation has not been systematically studied. We therefore performed a case-control study to evaluate the impact of the G2019S mutation status on the outcomes of bilateral STN-DBS. METHODS: The study sample included 39 Jewish PD patients with bilateral STN-DBS. Thirteen patients (5 females) were G2019S mutation heterozygous. The control group consisted of 26 PD patients with bilateral STN-DBS, negative for the mutation, matched (2:1) for gender, age at PD onset, and disease duration at surgery. Clinical data including the Unified PD Rating Scale scores (UPDRS), levodopa equivalent daily dose (LEDD), and clinical global impression of change (CGIC) concerning both motor and neuropsychiatric outcome- were available at 3 time points (preoperative baseline, 6-12 months and 3 years postoperatively). RESULTS: Implementing a linear mixed model, a significant improvement (p < 0.05) was found for the whole group concerning reduction in motor UPRDS (off state) and LEDD pre- vs. postoperatively, as expected. No difference in clinical outcome was found between carriers and matched non-carriers at baseline or at postoperative follow-up (up to 3 years). CONCLUSIONS: In our study, STN-DBS outcomes were not influenced by the LRRK2 G2019S mutation, and thus knowledge of carrier status may not be relevant to the considerations of patient selection for surgery. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/23932063/The_LRRK2_G2019S_mutation_status_does_not_affect_the_outcome_of_subthalamic_stimulation_in_patients_with_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(13)00257-5 DB - PRIME DP - Unbound Medicine ER -